Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2

S. S. Iyengar,R. Puri, S. N. Narasingan,D. R. Nair,V. Mehta,J. C. Mohan, S. K. Wangnoo,J. J. Dalal,V. Jha,S. Puri, A. Misra, M. K. Daga, M. Varma, S. Jasuja,S. Upadhyaya,R. R. Kasliwal,M. Bansal,R. Mehrotra,Anjly Jain,K. K. Talwar,R. Rajput,A. Pradhan,S. Seth,D. Kapoor, R. P. Melinkeri,S. Ramakrishnan,N. N. Khanna,R. Khadgawat, A. Shaikh, N. Kovalipati, N. Bordoloi,A. H. Zargar,R. K. Agarwal,A. Rastogi, M. Chag,D. Prabhakar, S. K. Mathur,H. Rehan, P. K. Sahoo, A. Dutta, A. Sharma,A. K. Pancholia,K. U. Natarajan, A. Mishra, K. Singh

Clinical Lipidology(2017)

引用 1|浏览25
暂无评分
摘要
These Lipid Association of India (LAI) recommendations refer to specific patient populations. They follow the previously published LAI part 1 recommendations. These part 2 LAI recommendations focus on specific patient groups. These include patients with heart failure, chronic kidney disease, non-alcoholic fatty liver disease, cerebrovascular disease, thyroid disorders, inflammatory joint diseases, familial hypercholesterolaemia and human immunodeficiency virus infection. We also consider women, the elderly and post-transplantation patients. The current recommendations are based, as much as possible, on available data from Indian populations.
更多
查看译文
关键词
dyslipidaemia,lipid
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要